Daiichi Sankyo and US giant Merck said their B7-H3 directed antibody drug conjugate (ADC) ifinatamab deruxtecan has been filed in the US for the treatment of extensive-stage small cell lung cancer (ES-SCLC). The drug, also known as I-DXd or DS-7300,…
To read the full story
Related Article
- Daiichi Sankyo’s ADC I-DXd Shows Distinct Safety Profile in SCLC: R&D Head
September 22, 2025
- Daiichi Sankyo Snares First FDA Breakthrough Tag for ADC I-DXd
August 20, 2025
BUSINESS
- Chiba Downpours Cause No Major Disruption to Drug Operations
August 17, 2026
- Chugai Files Tecentriq for Colon Cancer Adjuvant Therapy in Japan
August 17, 2026
- Enflonsia Filed for High-Risk Children in 2nd RSV Season in Japan: MSD
August 17, 2026
- Sawai to Drop 46 Generic Products, Takata 30
August 17, 2026
- Healios to File MultiStem in Japan Without Waiting for PIII Results: CEO
August 17, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





